Are atrial fibrillation patients receiving appropriate stroke prophylaxis?

British Journal of Cardiology

Volumn 8, Issue 1, 2001, Pages

  Gupta, A ^a   Thomas, P ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG CONTRAINDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PROPHYLAXIS; STROKE; THROMBOEMBOLISM;

EID: 0035150246     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Atrial fibrillation as an independent risk factor for stroke. The Framingham study
2. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older persons
3. Placebo controlled randomised trial of warfarin and aspirin for the prevention of thrombo-embolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
4. The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation
5. Stroke prevention in atrial fibrillation study: Final results
6. Canadian atrial fibrillation anticoagulation study (CAFA)
7. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in non-rheumatic Atrial Fibrillation Investigators
8. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation II Study
9. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attacks or minor stroke
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials
11. Antithrombotic therapies to prevent stroke in atrial fibrillation: A meta-analysis
12. Adjusted dose warfarin versus low intensity fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomised clinical trial
13. Survey of the use of anticoagulation in patients in atrial fibrillation
14. Atrial fibrillation and stroke prevention in the community
15. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US University hospital
16. Presentation and management of patients admitted with atrial fibrillation: A review of 291 cases in a regional hospital
17. Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation
18. Population based study of use of anticoagulants among patients with atrial fibrillation in the community
19. Is warfarin underused in the treatment of elderly persons with atrial fibrillation?
20. Underutilisation of warfarin in older persons with chronic non-valvular atrial fibrillation at high risk for developing stroke
21. Underutilisation of antithrombotic therapy in elderly rural patients with atrial fibrillation
22. Physician attitudes about anticoagulation for non-valvular atrial fibrillation in the elderly
23. Bleeding during antithrombotic therapy in patients with atrial fibrillation
24. Physician variation in anticoagulating patients with atrial fibrillation
25. The effect of age and quality of life on doctors' decisions to anticoagulate patients with atrial fibrillation
26. Warfarin anticoagulation in primary care: A regional survey of present practice and clinicians' views
27. Use of warfarin in non-rheumatic atrial fibrillation
28. Physicians' attitudes towards oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation
29. Physicians' attitudes concerning warfarin for stroke prevention in atrial fibrillation
30. Long term oral anticoagulant therapy in elderly patients
31. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
32. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and haemorrhage
33. Aging and the anticoagulant response to warfarin therapy
34. Risk factors for complications of chronic anticoagulation
35. Bleeding complications in oral anticoagulant therapy
36. Comorbidity increases the benefit of anticoagulation in patients with atrial fibrillation
37. Additional risk factors in atrial fibrillation patients not receiving warfarin
38. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: Variation in content and implications for treatment
39. Monitoring anticoagulation in primary care
40. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish National Perspective
41. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation
42. Anticoagulation in chronic nonvalvular atrial fibrillation: A critical appraisal and meta-analysis
43. Use of antithrombotic measures for stroke prevention in atrial fibrillation